| Project/Area Number |
02670982
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kyoto Pharmaceutical University (1991)
The University of Tokushima (1990) |
|---|
Principal Investigator |
SAKURAI Hiromu Kyoto pharmaceutical University, Faculty of Pharmaceutical Sciences Department of Analytical Chemistry Professor, 薬学部, 教授 (30065916)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKESHIMA Shigeo Kyoto Pharmaceutical University, Faculty of Pharmaceutical Sciences Department o, 薬学部, 助手 (60236461)
|
|---|
| Project Period (FY) |
1990 – 1991
|
| Project Status |
Completed (Fiscal Year 1991)
|
| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 1991: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1990: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | insulin-like action / vanadyl compounds / diabetes / streptozotocin / blood glucose level / vanadyl-cysteine methyl ester / vanadium determination / adipocites / ESR(電子スピン共鳴法) / 遊離脂肪酸 / 脂肪細胞 / 電子スピン共鳴(ESR) |
|---|
| Research Abstract |
We investigated whether vanadyl ion, which is less toxic than vanadate to rats, has an insulin-like effect in rats with streptozotocin (STZ) -induced diabetes. When rats with STZ -induced diabetes were given a daily i. p. injection of vanadyl sulfate or a daily p. o. admistration of vanadyl complexes like vanadyl-cysteine methyl ester (V-Cys), their blood glucose levels decreased to the normal level within 2 days and remained low for 12 weeks. These treatments did not affect their low plasma insulin levels. Quantitative electron spin resonance (ESR) spectrometry showed that most of the vanadium(-90%)in their tissues was present as a vanadyl form (VO^<2+>). Vanadium treatments accelerated glucose incorporation into adipocytes of rats suggesting that the action of vanadyl ion is peripheral. These results including that V-Cys showed anti-diabetic action when it was given orally, suggest that the vanadyl complexes are possible to use clinically to treat diabetes
|
